Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947925 | 0.82 | LPL (0.37) | ARCSF1RLPLLIPGKDM4E | |
| SCHEMBL16655447 | 0.80 | FPR2 (0.37) | CSF1RLPLLIPGKDM4EUSP2 | |
| SCHEMBL2656840 | 0.79 | KDM4E (0.40) | ARCSF1RLPLLIPGKDM4E | |
| SCHEMBL1668192 | 0.76 | TBK1 (0.39) | — | |
| SCHEMBL1667913 | 0.75 | ALDH1A1 (0.49) | ARCSF1RLPLLIPGKDM4E | |
| SCHEMBL421663 | 0.75 | AR (0.43) | ARCSF1RLPLLIPGKDM4E | |
| SCHEMBL2427133 | 0.73 | ESR2 (0.38) | LPLLIPGESR2 | |
| SCHEMBL21772422 | 0.73 | LPL (0.36) | LPLLIPGESR2 | |
| SCHEMBL30827381 | 0.73 | LPL (0.36) | CSF1RLPLLIPGKDM4EESR2 | |
| SCHEMBL20253387 | 0.73 | LPL (0.36) | CSF1RLPLLIPGKDM4EESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013034238-A1 | BENZONITRILE DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |